Ruth B. Girlando, APRN

Ruth Girlando practices at Endocrine Specialist PA in Naples, Florida.

Ruth Girlando's NPI, 1114991270, was assigned on February 15, 2006. Ruth Girlando holds Florida license ARNP3013702.

Ruth Girlando's primary practice is Endocrine Specialist PA, at 730 Goodlette N Rd, Naples, FL 34102 in Collier County. The practice phone is (239) 436-3666.

Ruth Girlando's primary practice is Endocrine Specialist PA in Naples, Florida. The medical group on file is Endocrine Specialists PA. Dmand AI also links Ruth Girlando to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ruth Girlando practices. Vendor and product names are available with a free account.

Nurse practitioner is Ruth Girlando's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Ruth Girlando is licensed in Florida.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, osteoporosis and underactive thyroid among the conditions Ruth Girlando treats.

CMS data shows 59 Medicare services from Ruth Girlando across 3 procedure codes in 2024, for 23 Medicare patients. Medicare paid $2,637 for them. Every service was in an office.

CMS counts 23 Medicare patients who saw Ruth Girlando in 2024. The largest group is 75 to 84, with 12 patients. 75% of them have high cholesterol, and 70% have high blood pressure. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Ruth Girlando's median patient age at 73, with 58% women.

In 2024, Ruth Girlando wrote 1,495 Medicare Part D claims for 411 patients. 56% of them were for generic drugs. CMS names the drug for 1,076 of them, across 31 drugs with 11 or more claims each, at $358,894 in total drug cost.

Ruth Girlando accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 93 general payments to Ruth Girlando from 29 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Eli Lilly and Company paid the most, $538.